~~<i id='5093798C93'><strike id='5093798C93'><tt id='5093798C93'><pre id='5093798C93'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：focus 2025-09-27 09:46:56 - browse：4383

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Virginia high school admissions case could be legal follow

entertainment

knowledge

focus

explore

knowledge

hotspot

3:41SulemanDawoodandShahzadaDawoodDawoodFamilyThefamilyoftwovictimsfromthesubmersiblethatimplodednea

WSS

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Medical records are filled with copy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

House panel to mark up pandemic

23andMe had bad news about my health. I wish a person had delivered it

hotspot

comprehensive

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

After affirmative action ruling, medical educators look to 'holistic review'

Titanic submersible: What a 'catastrophic implosion' means and what officials found

BioMarin wins approval for gene therapy to treat hemophilia A

Malaria cases in Florida and Texas: Here’s what you need to know

Duchenne breakthrough therapy leaves behind pioneering families

At least 13 dead in Texas as scorching temps continue

Moonlake's readout produced a cash windfall. Risks remain

Peter Hotez and the public health issue of online harassment

knowledge

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Drug repurposing or repositioning? The language matters

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In age of alternative facts, a scholarly course on calling out crap

The PBM ad wars are taking over Washington, D.C.

focus

explore

knowledge

hotspot